HC Wainwright Boosts Earnings Estimates for Krystal Biotech

Krystal Biotech, Inc. (NASDAQ:KRYS - Free Report) - Investment analysts at HC Wainwright upped their FY2026 earnings per share (EPS) estimates for shares of Krystal Biotech in a report issued on Monday, April 28th. HC Wainwright analyst J. Pantginis now expects that the company will post earnings of $6.30 per share for the year, up from their prior estimate of $6.23. HC Wainwright currently has a "Buy" rating and a $240.00 target price on the stock. The consensus estimate for Krystal Biotech's current full-year earnings is $6.14 per share. HC Wainwright also issued estimates for Krystal Biotech's FY2027 earnings at $8.56 EPS and FY2028 earnings at $9.85 EPS.

Krystal Biotech (NASDAQ:KRYS - Get Free Report) last posted its quarterly earnings results on Monday, February 24th. The company reported $1.52 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $1.29 by $0.23. Krystal Biotech had a net margin of 30.69% and a return on equity of 11.41%. The company had revenue of $91.10 million for the quarter, compared to the consensus estimate of $91.35 million. During the same period last year, the firm posted $0.30 EPS. The company's revenue for the quarter was up 116.4% on a year-over-year basis.

KRYS has been the topic of a number of other reports. Jefferies Financial Group initiated coverage on Krystal Biotech in a research report on Wednesday, March 5th. They set a "buy" rating and a $245.00 price target on the stock. Citigroup raised their target price on Krystal Biotech from $206.00 to $215.00 and gave the company a "neutral" rating in a research note on Thursday, February 20th. Chardan Capital upped their price target on shares of Krystal Biotech from $212.00 to $218.00 and gave the stock a "buy" rating in a research report on Thursday, February 20th. Finally, Cantor Fitzgerald reiterated an "overweight" rating and issued a $215.00 price objective on shares of Krystal Biotech in a research report on Thursday, February 20th. One equities research analyst has rated the stock with a hold rating, six have given a buy rating and one has assigned a strong buy rating to the company's stock. According to data from MarketBeat.com, the company currently has a consensus rating of "Buy" and a consensus target price of $222.71.

Krystal Biotech Trading Up 0.3 %

NASDAQ KRYS traded up $0.47 during trading hours on Thursday, reaching $166.16. The company's stock had a trading volume of 228,173 shares, compared to its average volume of 294,547. The business has a 50-day simple moving average of $174.92 and a 200 day simple moving average of $171.25. Krystal Biotech has a 52 week low of $141.72 and a 52 week high of $219.34. The stock has a market cap of $4.80 billion, a PE ratio of 55.57 and a beta of 0.79.

Institutional Investors Weigh In On Krystal Biotech

Several large investors have recently modified their holdings of the stock. FMR LLC increased its stake in Krystal Biotech by 0.5% in the 4th quarter. FMR LLC now owns 4,314,014 shares of the company's stock worth $675,833,000 after purchasing an additional 21,133 shares in the last quarter. Vanguard Group Inc. raised its holdings in shares of Krystal Biotech by 1.0% during the fourth quarter. Vanguard Group Inc. now owns 2,878,451 shares of the company's stock valued at $450,938,000 after acquiring an additional 28,707 shares during the period. Avoro Capital Advisors LLC lifted its position in shares of Krystal Biotech by 0.3% in the 4th quarter. Avoro Capital Advisors LLC now owns 2,628,822 shares of the company's stock valued at $411,831,000 after acquiring an additional 6,600 shares in the last quarter. Hood River Capital Management LLC boosted its stake in Krystal Biotech by 2.1% in the 4th quarter. Hood River Capital Management LLC now owns 512,726 shares of the company's stock worth $80,324,000 after purchasing an additional 10,622 shares during the period. Finally, Price T Rowe Associates Inc. MD grew its position in Krystal Biotech by 16.2% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 509,459 shares of the company's stock worth $79,812,000 after purchasing an additional 71,200 shares in the last quarter. 86.29% of the stock is owned by institutional investors.

Insider Activity at Krystal Biotech

In related news, insider Suma Krishnan sold 25,000 shares of the firm's stock in a transaction dated Thursday, March 13th. The stock was sold at an average price of $177.79, for a total transaction of $4,444,750.00. Following the completion of the transaction, the insider now owns 1,463,711 shares of the company's stock, valued at $260,233,178.69. This trade represents a 1.68 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, CAO Kathryn Romano sold 750 shares of the firm's stock in a transaction dated Thursday, February 27th. The shares were sold at an average price of $175.22, for a total transaction of $131,415.00. Following the transaction, the chief accounting officer now owns 12,604 shares of the company's stock, valued at approximately $2,208,472.88. This trade represents a 5.62 % decrease in their position. The disclosure for this sale can be found here. 13.70% of the stock is currently owned by insiders.

About Krystal Biotech

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).